Vildagliptin induced cutaneous leukocytoclastic vasculitis: A case report

Vildagliptin induced cutaneous leukocytoclastic vasculitis: A case report

Vildagliptin is a new generation theurapeutic agent of diabetes mellitus which belongs to dipeptidyl peptidase-IV inhibitor class acting via the incretin hormone system. It has moderate glycemic efficacy, a low propensity of causing hypoglycaemia and it is weight neutral. Overall, Dipeptidyl peptida...

Full description

Bibliographic Details
Main Authors:	Serhat Sayin, Ethem Omeroglu, Semra Aslan Bilgin
Format:	Article
Language:	English
Published:	Society of Turaz Bilim 2018-03-01
Series:	Medicine Science
Subjects:	Vildagliptin Vasculitis diabetes mellitus
Online Access:	http://www.ejmanager.com/fulltextpdf.php?mno=265066

Similar Items

Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients
by: Chin-Hsiao Tseng, et al.
Published: (2021-04-01)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
by: Paresh Ved, et al.
Published: (2012-01-01)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
by: Hyun Jeong Jeon, et al.
Published: (2011-10-01)

Cutaneous leukocytoclastic vasculitis associated with levofloxacin therapy
by: Dana Blyth, et al.
Published: (2012-01-01)

An uncommon coexistence of sarcoidosis and cutaneous leukocytoclastic vasculitis in an adult
by: Birsen Ocakli, et al.
Published: (2019-01-01)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
by: Elena Valer'evna Biryukova
Published: (2014-03-01)

EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
by: Gagik Radikovich Galstyan
Published: (2013-06-01)

Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke
by: Dong‐Yi Chen, et al.
Published: (2020-01-01)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
by: Asima Khan, et al.
Published: (2022-08-01)

Mild acute pancreatitis with vildagliptin use
by: Ravikant Saraogi, et al.
Published: (2012-01-01)

Budget impact of vildagliptin
by: Orietta Zaniolo, et al.
Published: (2008-09-01)

Efficacy and pathogenetic justification for the use of vildagliptin in patients with type 2 diabetes mellitus
by: V.I. Pankiv
Published: (2019-10-01)

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
by: Hara Kousoulakou, et al.
Published: (2017-09-01)

Cutaneous leukocytoclastic vasculitis associated with verapamil and atorvastatin: A case report
by: Yi Tong Vincent Aw, et al.
Published: (2023-07-01)

Tyrosine Kinase Inhibitors - Induced Cutaneous Leukocytoclastic Vasculitis
by: Diogo Alpuim Costa, et al.
Published: (2018-05-01)

Drug-induced leukocytoclastic vasculitis: tigecycline a rare cause
by: Kalpana Bhairavarasu, et al.
Published: (2015-01-01)

Leukocytoclastic vasculitis in T‐cell lymphoma
by: Ming Y. Lim
Published: (2020-12-01)

Propylthiouracil induced leukocytoclastic vasculitis: A rare manifestation
by: Semra Ayturk, et al.
Published: (2013-01-01)

Leukocytoclastic vasculitis in a patient with ankylosing spondylitis: A case report
by: Alireza Khabbazi, et al.
Published: (2024-04-01)

A Randomized, Two-Treatments, Two-Periods, Crossover, Open label, Laboratory-Blind, Single Dose Bioequivalence Study between Vildagliptin/Metformin 50 mg/1000 mg Film Coated Tablets (Sensityn®) and Galvusmet® 50 mg/1000 mg Film Coated Tablets in healthy adults under fed conditions
by: Shiekmydeen J., et al.
Published: (2023-10-01)

Perbedaan Efektivitas Penggunaan Metformin-Insulin versus Metformin-Vildagliptin Terhadap Profil Glikemik Pasien DMT2 di Instalasi Rawat Jalan RSISA Periode 2022
by: Willi Wahyu Timur, et al.
Published: (2024-05-01)

Methimazole-Induced Leukocytoclastic Vasculitis: A Case Report
by: Weeratian Tawanwongsri, et al.
Published: (2019-11-01)

Tofacitinib Treatment of Refractory Cutaneous Leukocytoclastic Vasculitis: A Case Report
by: Kai-Jun Zhu, et al.
Published: (2021-06-01)

Leukocytoclastic vasculitis as a cutaneous paraneoplastic syndrome in malignant mesothelioma
by: Hyeok-Jin Kwon, MD, et al.
Published: (2022-08-01)

Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: An Exclusion Diagnosis of a Multidisciplinary Approach
by: Diogo Alpuim Costa, et al.
Published: (2017-11-01)

Annular leukocytoclastic vasculitis: a new feature of IgA vasculitis
by: Nabil Belfeki, et al.
Published: (2024-04-01)

Dengue associated with severe cutaneous leukocytoclastic vasculitis and pericardial effusion: a case report
by: Laurisson Albuquerque da Costa, et al.
Published: (2020-12-01)

Leukocytoclastic Vasculitis Induced by Cocaine Adulterated with Levamisole
by: Alberto Barbotti, et al.
Published: (2022-07-01)

Novel Inflammatory Markers Associated With Cutaneous Leukocytoclastic Vasculitis Etiology
by: Omar Dhrif, et al.
Published: (2024-08-01)

EFFECT OF PHARMACOLOGICAL PRECONDITIONING WITH INCRETINOMIMETICS EXENATIDE AND VILDAGLIPTIN ON THE SURVIVAL OF ISCHEMIC TISSUES
by: Alla Tarasova, et al.
Published: (2017-12-01)

Adalimumab‐induced leukocytoclastic vasculitis in a patient with ankylosing spondylitis: A case report
by: Alireza Khabbazi, et al.
Published: (2024-08-01)

Mycoplasmal upper respiratory infection presenting as leukocytoclastic vasculitis
by: Mana Rao, et al.
Published: (2015-02-01)

Comparative Evaluation of Vildagliptin-Metformin Versus Glimepiride-Metformin on Inflammatory Markers and Glycemic Control in Type 2 Diabetes Mellitus: A Randomized, Open-Label Study
by: Navreet Kaur, et al.
Published: (2024-07-01)

Cutaneous leukocytoclastic vasculitis secondary to COVID‐19 infection: A case report
by: Fariba Iraji, et al.
Published: (2021-02-01)

Reprotoxic activities of vildagliptin administration in male Wistar rats
by: Akinsomisoye Olumide Stephen, et al.
Published: (2021-11-01)

Nanofibrous insulin/vildagliptin core-shell PLGA scaffold promotes diabetic wound healing
by: Chen-Hung Lee, et al.
Published: (2023-04-01)

Results of a clinical trial of the efficacy and safety of vildagliptin and metformin fixed combination in real clinical practice in Russia (MASTER study)
by: N. A. Demidov, et al.
Published: (2021-02-01)

Metformin Sustained-Release and Vildagliptin Fixed-Dose Combination for Optimizing Glycemic Control: A Review with Real-World Case Reports
by: Manoj Chawla, et al.
Published: (2023-03-01)

Leukocytoclastic Vasculitis of the Breast: A Case Report
by: Taeyang Ha, et al.
Published: (2018-04-01)

Engineered vildagliptin-loaded polymeric nanoparticles via microfluidic and spray drying for enhanced antidiabetic activity
by: Eknath Kole, et al.
Published: (2024-11-01)